Compare FirstEnergy Corp. (FE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Viatris Inc — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.10B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| FE | VTRS | |
|---|---|---|
Market Cap | $27.10B | $18.69B |
Sector | Utilities | Health |
52-Week High | $51.91 | $17.86 |
52-Week Low | $42.83 | $9.49 |
Enterprise Value | $56.02B | $30.80B |
Dividend Yield | 3.97% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $46.95, up 0.41% with a bearish technical outlook despite recent earnings beats. The utility company shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though earnings have been mixed with two recent misses. Analyst sentiment is cautiously optimistic with a $52.67 price target, while institutional buying activity indicates confidence in the company's $36B grid investment plan and data center demand growth.
FE presents a defensive investment opportunity with visible earnings growth from infrastructure investments, but faces execution risks on capital projects and regulatory uncertainty. The stock's current valuation at 25x P/E appears reasonable given the 6-8% EPS growth guidance, though high debt levels and interest expenses remain concerns for margin expansion.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
